Literature DB >> 25548287

O-linked glycosylation of the mucin domain of the herpes simplex virus type 1-specific glycoprotein gC-1 is temporally regulated in a seed-and-spread manner.

Rickard Nordén1, Adnan Halim2, Kristina Nyström1, Eric P Bennett3, Ulla Mandel3, Sigvard Olofsson1, Jonas Nilsson4, Göran Larson5.   

Abstract

The herpes simplex virus type 1 (HSV-1) glycoprotein gC-1, participating in viral receptor interactions and immunity interference, harbors a mucin-like domain with multiple clustered O-linked glycans. Using HSV-1-infected diploid human fibroblasts, an authentic target for HSV-1 infection, and a protein immunoaffinity procedure, we enriched fully glycosylated gC-1 and a series of its biosynthetic intermediates. This fraction was subjected to trypsin digestion and a LC-MS/MS glycoproteomics approach. In parallel, we characterized the expression patterns of the 20 isoforms of human GalNAc transferases responsible for initiation of O-linked glycosylation. The gC-1 O-glycosylation was regulated in an orderly manner initiated by synchronous addition of one GalNAc unit each to Thr-87 and Thr-91 and one GalNAc unit to either Thr-99 or Thr-101, forming a core glycopeptide for subsequent additions of in all 11 GalNAc residues to selected Ser and Thr residues of the Thr-76-Lys-107 stretch of the mucin domain. The expression patterns of GalNAc transferases in the infected cells suggested that initial additions of GalNAc were carried out by initiating GalNAc transferases, in particular GalNAc-T2, whereas subsequent GalNAc additions were carried out by followup transferases, in particular GalNAc-T10. Essentially all of the susceptible Ser or Thr residues had to acquire their GalNAc units before any elongation to longer O-linked glycans of the gC-1-associated GalNAc units was permitted. Because the GalNAc occupancy pattern is of relevance for receptor binding of gC-1, the data provide a model to delineate biosynthetic steps of O-linked glycosylation of the gC-1 mucin domain in HSV-1-infected target cells.
© 2015 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  Glycoprotein Biosynthesis; Glycosylation; Glycosyltransferase; Herpesvirus; Mass Spectrometry (MS)

Mesh:

Substances:

Year:  2014        PMID: 25548287      PMCID: PMC4335243          DOI: 10.1074/jbc.M114.616409

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  51 in total

1.  Probing polypeptide GalNAc-transferase isoform substrate specificities by in vitro analysis.

Authors:  Yun Kong; Hiren J Joshi; Katrine Ter-Borch Gram Schjoldager; Thomas Daugbjerg Madsen; Thomas A Gerken; Malene B Vester-Christensen; Hans H Wandall; Eric Paul Bennett; Steven B Levery; Sergey Y Vakhrushev; Henrik Clausen
Journal:  Glycobiology       Date:  2014-08-25       Impact factor: 4.313

2.  A novel human UDP-N-acetyl-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase, GalNAc-T7, with specificity for partial GalNAc-glycosylated acceptor substrates.

Authors:  E P Bennett; H Hassan; M A Hollingsworth; H Clausen
Journal:  FEBS Lett       Date:  1999-10-29       Impact factor: 4.124

Review 3.  Control of mucin-type O-glycosylation: a classification of the polypeptide GalNAc-transferase gene family.

Authors:  Eric P Bennett; Ulla Mandel; Henrik Clausen; Thomas A Gerken; Timothy A Fritz; Lawrence A Tabak
Journal:  Glycobiology       Date:  2011-12-18       Impact factor: 4.313

4.  Diverse IgG serum response to novel glycopeptide epitopes detected within immunodominant stretches of Epstein-Barr virus glycoprotein 350/220: diagnostic potential of O-glycopeptide microarrays.

Authors:  Isotta D'Arrigo; Emiliano Cló; Tomas Bergström; Sigvard Olofsson; Ola Blixt
Journal:  Glycoconj J       Date:  2013-01-08       Impact factor: 2.916

5.  The lectin domain of UDP-N-acetyl-D-galactosamine: polypeptide N-acetylgalactosaminyltransferase-T4 directs its glycopeptide specificities.

Authors:  H Hassan; C A Reis; E P Bennett; E Mirgorodskaya; P Roepstorff; M A Hollingsworth; J Burchell; J Taylor-Papadimitriou; H Clausen
Journal:  J Biol Chem       Date:  2000-12-08       Impact factor: 5.157

Review 6.  Location, location, location: new insights into O-GalNAc protein glycosylation.

Authors:  David J Gill; Henrik Clausen; Frederic Bard
Journal:  Trends Cell Biol       Date:  2010-12-08       Impact factor: 20.808

7.  Real time PCR for monitoring regulation of host gene expression in herpes simplex virus type 1-infected human diploid cells.

Authors:  Kristina Nyström; Marlene Biller; Ammi Grahn; Magnus Lindh; Göran Larson; Sigvard Olofsson
Journal:  J Virol Methods       Date:  2004-06-15       Impact factor: 2.014

Review 8.  Recent issues in herpes simplex encephalitis.

Authors:  Peter G E Kennedy; Israel Steiner
Journal:  J Neurovirol       Date:  2013-06-18       Impact factor: 2.643

Review 9.  All in the family: the UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferases.

Authors:  Kelly G Ten Hagen; Timothy A Fritz; Lawrence A Tabak
Journal:  Glycobiology       Date:  2002-11-01       Impact factor: 4.313

10.  Antibody evasion by a gammaherpesvirus O-glycan shield.

Authors:  Bénédicte Machiels; Céline Lété; Antoine Guillaume; Jan Mast; Philip G Stevenson; Alain Vanderplasschen; Laurent Gillet
Journal:  PLoS Pathog       Date:  2011-11-17       Impact factor: 6.823

View more
  11 in total

1.  A validated collection of mouse monoclonal antibodies to human glycosyltransferases functioning in mucin-type O-glycosylation.

Authors:  Catharina Steentoft; Zhang Yang; Shengjun Wang; Tongzhong Ju; Malene B Vester-Christensen; María F Festari; Sarah L King; Kelley Moremen; Ida S B Larsen; Christoffer K Goth; Katrine T Schjoldager; Lars Hansen; Eric P Bennett; Ulla Mandel; Yoshiki Narimatsu
Journal:  Glycobiology       Date:  2019-08-20       Impact factor: 4.313

Review 2.  Liquid chromatography-tandem mass spectrometry-based fragmentation analysis of glycopeptides.

Authors:  Jonas Nilsson
Journal:  Glycoconj J       Date:  2016-01-18       Impact factor: 2.916

3.  Mucin-type O-glycosylation is controlled by short- and long-range glycopeptide substrate recognition that varies among members of the polypeptide GalNAc transferase family.

Authors:  Leslie Revoredo; Shengjun Wang; Eric Paul Bennett; Henrik Clausen; Kelley W Moremen; Donald L Jarvis; Kelly G Ten Hagen; Lawrence A Tabak; Thomas A Gerken
Journal:  Glycobiology       Date:  2015-11-26       Impact factor: 4.313

4.  Global Mapping of O-Glycosylation of Varicella Zoster Virus, Human Cytomegalovirus, and Epstein-Barr Virus.

Authors:  Ieva Bagdonaite; Rickard Nordén; Hiren J Joshi; Sarah L King; Sergey Y Vakhrushev; Sigvard Olofsson; Hans H Wandall
Journal:  J Biol Chem       Date:  2016-04-15       Impact factor: 5.157

Review 5.  Exploitation of glycosylation in enveloped virus pathobiology.

Authors:  Yasunori Watanabe; Thomas A Bowden; Ian A Wilson; Max Crispin
Journal:  Biochim Biophys Acta Gen Subj       Date:  2019-05-20       Impact factor: 3.770

6.  Global aspects of viral glycosylation.

Authors:  Ieva Bagdonaite; Hans H Wandall
Journal:  Glycobiology       Date:  2018-07-01       Impact factor: 4.313

Review 7.  A Roadmap for the Molecular Farming of Viral Glycoprotein Vaccines: Engineering Glycosylation and Glycosylation-Directed Folding.

Authors:  Emmanuel Margolin; Max Crispin; Ann Meyers; Ros Chapman; Edward P Rybicki
Journal:  Front Plant Sci       Date:  2020-12-03       Impact factor: 5.753

Review 8.  Glycosylation of viral proteins: Implication in virus-host interaction and virulence.

Authors:  Tingting Feng; Jinyu Zhang; Zhiqian Chen; Wen Pan; Zhengrong Chen; Yongdong Yan; Jianfeng Dai
Journal:  Virulence       Date:  2022-12       Impact factor: 5.428

Review 9.  Site-specific glycosylation of SARS-CoV-2: Big challenges in mass spectrometry analysis.

Authors:  Diana Campos; Michael Girgis; Miloslav Sanda
Journal:  Proteomics       Date:  2022-06-22       Impact factor: 5.393

10.  Synthetic Carbohydrate Chemistry and Translational Medicine.

Authors:  Sachin S Shivatare; Chi-Huey Wong
Journal:  J Org Chem       Date:  2020-10-30       Impact factor: 4.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.